Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023
Recently, the remarkable success of chimeric antigen receptor T cell (CAR-T) therapy in treating certain tumors has led to numerous studies exploring its potential application to treat non-oncology diseases. This review discusses the progress and evolution of CAR-T cell therapies for treating non-on...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2251839 |
| _version_ | 1797633696473284608 |
|---|---|
| author | Ming-Yao Sun Wanyang Li Wei Chen |
| author_facet | Ming-Yao Sun Wanyang Li Wei Chen |
| author_sort | Ming-Yao Sun |
| collection | DOAJ |
| description | Recently, the remarkable success of chimeric antigen receptor T cell (CAR-T) therapy in treating certain tumors has led to numerous studies exploring its potential application to treat non-oncology diseases. This review discusses the progress and evolution of CAR-T cell therapies for treating non-oncology diseases over the past 5 years. Additionally, we summarize the advantages and disadvantages of CAR-T cell therapy in treating non-oncological diseases and identify any difficulties that should be overcome. After conducting an in-depth analysis of the most recent studies on CAR-T technology, we discuss the key elements of CAR-T therapy, such as developing an effective CAR design for non-oncological diseases, controlling the rate and duration of response, and implementing safety measures to reduce toxicity. These studies provide new insights into different delivery strategies, the discovery of new target molecules, and improvements in the safety of CAR-T therapy for non-oncological diseases. |
| first_indexed | 2024-03-11T11:57:30Z |
| format | Article |
| id | doaj.art-22edf984286848f3af8c6d232f9cd383 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T11:57:30Z |
| publishDate | 2023-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-22edf984286848f3af8c6d232f9cd3832023-11-08T11:55:20ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-08-0119210.1080/21645515.2023.22518392251839Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023Ming-Yao Sun0Wanyang Li1Wei Chen2Peking Union Medical College HospitalPeking Union Medical College HospitalPeking Union Medical College HospitalRecently, the remarkable success of chimeric antigen receptor T cell (CAR-T) therapy in treating certain tumors has led to numerous studies exploring its potential application to treat non-oncology diseases. This review discusses the progress and evolution of CAR-T cell therapies for treating non-oncology diseases over the past 5 years. Additionally, we summarize the advantages and disadvantages of CAR-T cell therapy in treating non-oncological diseases and identify any difficulties that should be overcome. After conducting an in-depth analysis of the most recent studies on CAR-T technology, we discuss the key elements of CAR-T therapy, such as developing an effective CAR design for non-oncological diseases, controlling the rate and duration of response, and implementing safety measures to reduce toxicity. These studies provide new insights into different delivery strategies, the discovery of new target molecules, and improvements in the safety of CAR-T therapy for non-oncological diseases.http://dx.doi.org/10.1080/21645515.2023.2251839chimeric antigen receptorchimeric t cell receptorscar-t cell therapynon-oncology diseasesimmunotherapy |
| spellingShingle | Ming-Yao Sun Wanyang Li Wei Chen Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023 Human Vaccines & Immunotherapeutics chimeric antigen receptor chimeric t cell receptors car-t cell therapy non-oncology diseases immunotherapy |
| title | Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023 |
| title_full | Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023 |
| title_fullStr | Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023 |
| title_full_unstemmed | Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023 |
| title_short | Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023 |
| title_sort | chimeric antigen receptor t cell and regulatory t cell therapy in non oncology diseases a narrative review of studies from 2017 to 2023 |
| topic | chimeric antigen receptor chimeric t cell receptors car-t cell therapy non-oncology diseases immunotherapy |
| url | http://dx.doi.org/10.1080/21645515.2023.2251839 |
| work_keys_str_mv | AT mingyaosun chimericantigenreceptortcellandregulatorytcelltherapyinnononcologydiseasesanarrativereviewofstudiesfrom2017to2023 AT wanyangli chimericantigenreceptortcellandregulatorytcelltherapyinnononcologydiseasesanarrativereviewofstudiesfrom2017to2023 AT weichen chimericantigenreceptortcellandregulatorytcelltherapyinnononcologydiseasesanarrativereviewofstudiesfrom2017to2023 |